Article info

PDF
Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ

Authors

  1. Correspondence to Professor Xu Li, Center for Molecular Medicine, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China; lixu1956{at}gmail.com
View Full Text

Citation

Hou H, Chen W, Zhao L, et al
Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ

Publication history

  • Accepted July 25, 2012
  • First published September 3, 2012.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.